{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T10:25:59Z","timestamp":1782210359377,"version":"3.54.5"},"reference-count":37,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2026,3,15]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Mutations in genes encoding proteins involved the DNA damage response (DDR) occur in up to 20% of patients with cancer. It is unknown whether poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors, alone or in combination with ATR or AKT inhibitors, have histology\u2010agnostic clinical efficacy in tumors with DDR mutations or PI3K\/AKT pathway mutations, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The Olaparib Combinations (OLAPCO) trial enrolled patients in treatment arms based on next\u2010generation sequencing results. In cohorts 1 and 2, patients with tumors harboring DDR mutations received either the PARP inhibitor olaparib or olaparib and the ATR inhibitor ceralasertib. In cohort 3, patients with tumors with PI3K\u2010AKT pathway alterations or ARID1A mutations received olaparib and capivasertib. The primary end point was overall response rate (ORR) at 16 weeks assessed by the Response Evaluation Criteria in Solid Tumors, version 1.1.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Sixty\u2010six patients were treated, including 26 on olaparib monotherapy, 24 on olaparib and ceralasertib, and 16 on olaparib and capivasertib. Among all patients treated, the ORR was 6.1% and the clinical benefit rate was 31.2% with a median duration of benefit (DoB) of 11 months. Among seven patients with platinum\u2010 and PARP inhibitor\u2010resistant high\u2010grade ovarian serous cancer in the olaparib and ceralasertib arm, one had a partial response and four had stable disease with a median DoB of 10 months. No unexpected toxicities were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The study failed to meet its primary end point of ORR. DDR and homologous recombination repair defects are not consistently actionable with olaparib as monotherapy or in combination with other targeted therapies in a histology\u2010agnostic manner.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cncr.70332","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T08:24:51Z","timestamp":1773217491000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeted therapy for DNA damage response and homologous recombination repair defects: The Olaparib Combinations trial"],"prefix":"10.1002","volume":"132","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2221-9818","authenticated-orcid":false,"given":"Deborah B.","family":"Doroshow","sequence":"first","affiliation":[{"name":"Yale Cancer Center  New Haven Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey I.","family":"Shapiro","sequence":"additional","affiliation":[{"name":"Dana\u2010Farber Cancer Institute  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khanh","family":"Do","sequence":"additional","affiliation":[{"name":"Dana\u2010Farber Cancer Institute  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicki L.","family":"Keedy","sequence":"additional","affiliation":[{"name":"Vanderbilt\u2010Ingram Cancer Center  Nashville Tennessee USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haider","family":"Mahdi","sequence":"additional","affiliation":[{"name":"University of Pittsburgh Medical Center  Pittsburgh Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davendra P. S.","family":"Sohal","sequence":"additional","affiliation":[{"name":"Cleveland Clinic  Cleveland Ohio USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navid","family":"Hafez","sequence":"additional","affiliation":[{"name":"Yale Cancer Center  New Haven Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia M.","family":"LoRusso","sequence":"additional","affiliation":[{"name":"Yale Cancer Center  New Haven Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3504-0128","authenticated-orcid":false,"given":"Michael","family":"Cecchini","sequence":"additional","affiliation":[{"name":"Yale Cancer Center  New Haven Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Sklar","sequence":"additional","affiliation":[{"name":"Yale Cancer Center  New Haven Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Mortimer","sequence":"additional","affiliation":[{"name":"AstraZeneca  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Glover","sequence":"additional","affiliation":[{"name":"AstraZeneca  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Moses","sequence":"additional","affiliation":[{"name":"Yale Cancer Center  New Haven Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliane M.","family":"J\u00fcrgensmeier","sequence":"additional","affiliation":[{"name":"Yale Cancer Center  New Haven Connecticut USA"},{"name":"Independent Consultant"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph P.","family":"Eder","sequence":"additional","affiliation":[{"name":"Yale Cancer Center  New Haven Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.03.076"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/po.17.00286"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.01.002"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2015.21"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(21)00073\u20105"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1706450"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2017.02.001"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/23808993.2019.1623023"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aal2463"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1714448"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159\u20108290.cd\u201018\u20100338"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467\u2010020\u201017127\u20102"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/po.20.00247"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/PO.20.00439"},{"key":"e_1_2_9_16_1","unstructured":"Food and Drug Administration.Oncology (Cancer)\/Hematologic Malignancies Approval Notifications. Accessed January 30 2025.https:\/\/www.fda.gov\/drugs\/resources\u2010information\u2010approved\u2010drugs\/oncology\u2010cancerhematologic\u2010malignancies\u2010approval\u2010notifications"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.8b01187"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201022\u20102444"},{"key":"e_1_2_9_19_1","unstructured":"Food and Drug Administration.FDA approves capivasertib with fulvestrant for breast cancer. Accessed January 30 2025.https:\/\/www.fda.gov\/drugs\/resources\u2010information\u2010approved\u2010drugs\/fda\u2010approves\u2010capivasertib\u2010fulvestrant\u2010breast\u2010cancer"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159\u20108290.CD\u201011\u20100348"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538\u20107445.am2014\u20104759"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885\u2010017\u20103639\u20100"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.ccr\u201021\u20101656"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/0197\u20102456(89)90015\u20109"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1600"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13205230"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2016\u20100527\u2010oa"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(10)60893\u20108"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(10)60892\u20106"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.17005"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw133"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1506859"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.02151"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1911440"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41588\u2010018\u20100170\u20104"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.ccr\u201018\u20104212"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1158\/2767\u20109764.crc\u201022\u20100436"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35755"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.70332","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cncr.70332","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.70332","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T04:41:28Z","timestamp":1775536888000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.70332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,3,15]]}},"alternative-id":["10.1002\/cncr.70332"],"URL":"https:\/\/doi.org\/10.1002\/cncr.70332","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,11]]},"assertion":[{"value":"2025-08-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70332"}}